Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Preferred Stock Liabilities (2016 - 2025)

Wave Life Sciences' Preferred Stock Liabilities history spans 11 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, changed 0.0%, while the annual FY2025 figure was $7.9 million, 0.0% changed from the prior year.
  • Preferred Stock Liabilities reached $7.9 million in Q4 2025 per WVE's latest filing, roughly flat from $7.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $7.9 million in Q1 2021 to a low of $7.9 million in Q1 2021.
  • Average Preferred Stock Liabilities over 5 years is $7.9 million, with a median of $7.9 million recorded in 2021.
  • The largest YoY upside for Preferred Stock Liabilities was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $7.9 million in 2021, then changed by 0.0% to $7.9 million in 2022, then changed by 0.0% to $7.9 million in 2023, then changed by 0.0% to $7.9 million in 2024, then changed by 0.0% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Preferred Stock Liabilities are $7.9 million (Q4 2025), $7.9 million (Q3 2025), and $7.9 million (Q2 2025).